Evidence map›Paper›PMID 42403913›Full record

Trial reportOpen forum infectious diseases2026

Three-Year CD4/CD8 Ratio Recovery After Initiation of Dual Versus Triple Integrase Inhibitor-Based Therapy in Naïve Adults With HIV.

Roser Navarro-Soler, Alejandro G García-Ruiz de Morales, Juan Macías, Jorge Sánchez-Villegas, José Luis Blanco Arévalo, Dàcil García Rosado, Antonio Ocampo Hermida, Cristina Gómez Ayerbe, Santiago Moreno, Javier Martínez-Sanz and 1 more

Abstract readClinical Trial
In one paragraph

Trial report in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Roser Navarro-SolerDepartment of Infectious Diseases, Hospital Ramón y Cajal, IRYCIS, Madrid, Spain.ORCID https://orcid.org/0009-0001-7044-2707
Alejandro G García-Ruiz de MoralesDepartment of Infectious Diseases, Hospital Ramón y Cajal, IRYCIS, Madrid, Spain.ORCID https://orcid.org/0000-0003-4896-6528
Juan MacíasCIBERINFEC, Carlos III Health Institute, Madrid, Spain.ORCID https://orcid.org/0000-0002-4778-790X
Jorge Sánchez-VillegasClinical Unit for Infectious Diseases and Microbiology, Hospital Universitario Virgen de la Macarena IBiS, CSIC, Universidad de Sevilla, Sevilla, Spain.
José Luis Blanco ArévaloCIBERINFEC, Carlos III Health Institute, Madrid, Spain.
Dàcil García RosadoInfectious Diseases Section, Internal Medicine Department, Hospital Universitario de Canarias, Canarias, Spain.
Antonio Ocampo HermidaInternal Medicine Department, Hospital Álvaro Cunqueiro, Galicia, Spain.
Cristina Gómez AyerbeInfectious Diseases Unit, Hospital Universitario Virgen de la Victoria, IBIMA-Plataforma BIONAND, Málaga, Spain.
Santiago MorenoDepartment of Infectious Diseases, Hospital Ramón y Cajal, IRYCIS, Madrid, Spain.ORCID https://orcid.org/0000-0002-2843-1094
Javier Martínez-SanzDepartment of Infectious Diseases, Hospital Ramón y Cajal, IRYCIS, Madrid, Spain.ORCID https://orcid.org/0000-0003-2020-3908
Sergio Serrano-VillarDepartment of Infectious Diseases, Hospital Ramón y Cajal, IRYCIS, Madrid, Spain.ORCID https://orcid.org/0000-0002-5447-3554

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

From 21 233 adults in the Spanish HIV Research Network, we used propensity score matching to compare CD4/CD8 ratio recovery between dolutegravir-based 2DR and second-generation integrase inhibitor-based 3DR. No detectable differences in CD4/CD8 normalization were observed at 3 years across all cutoffs, suggesting that immune recovery does not differ between strategies.

Indexed as

CD4/CD8 ratioHIVintegrase inhibitors; 2-drug regimen; 3-drug regimen

Identifiers

PMID42403913
PMCPMC13329665

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.